Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 24298013
Arneja A, et al. (2014) Qualitatively different T cell phenotypic responses to IL-2 versus IL-15 are unified by identical dependences on receptor signal strength and duration. J Immunol 192, 123-35 24298013
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

Y827-p - Ack (human)
Modsite: SFASDPkyAtPQVIQ SwissProt Entrez-Gene
Orthologous residues
Ack (human): Y827‑p, Ack iso3 (human): Y905‑p, Ack (mouse): Y842‑p, Ack iso2 (mouse): Y827‑p, Ack (rat): Y827‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

Y198-p - ACTB (human)
Modsite: kILtERGysFtttAE SwissProt Entrez-Gene
Orthologous residues
ACTB (human): Y198‑p, ACTB (mouse): Y198‑p, ACTB (rat): Y198‑p, ACTB (cow): Y198‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y198-p - ACTG1 (human)
Modsite: kILtERGysFtttAE SwissProt Entrez-Gene
Orthologous residues
ACTG1 (human): Y198‑p, ACTG1 (mouse): Y198‑p, ACTG1 (rat): Y198‑p

Y446-p - ADD3 (human)
Modsite: WLNsPNtyMkVNVPE SwissProt Entrez-Gene
Orthologous residues
ADD3 (human): Y446‑p, ADD3 iso2 (human): Y446‑p, ADD3 (mouse): Y446‑p, ADD3 iso2 (mouse): Y446‑p, ADD3 (rat): Y446‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

S135-p - AHNAK (human)
Modsite: kIkPRLksEDGVEGD SwissProt Entrez-Gene
Orthologous residues
AHNAK (human): S135‑p, AHNAK iso2 (human): , AHNAK (mouse): S136‑p, AHNAK (rat): S136‑p, AHNAK iso2 (rat): S136‑p, AHNAK (cow): S136‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y160-p - AHNAK (human)
Modsite: VtRRVtAytVDVTGR SwissProt Entrez-Gene
Orthologous residues
AHNAK (human): Y160‑p, AHNAK iso2 (human): , AHNAK (mouse): Y161‑p, AHNAK (rat): Y161‑p, AHNAK iso2 (rat): Y161‑p, AHNAK (cow): Y161‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

Y182-p - ARL6IP5 (human)
Modsite: GINRLtDyISkVKE_ SwissProt Entrez-Gene
Orthologous residues
ARL6IP5 (human): Y182‑p, ARL6IP5 (mouse): Y182‑p, ARL6IP5 (rat): Y182‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

Y65-p - ARPP-19 (human)
Modsite: kyFDsGDyNMAkAkM SwissProt Entrez-Gene
Orthologous residues
ARPP‑19 (human): Y65‑p, ARPP‑19 iso2 (human): Y49‑p, ARPP‑19 (mouse): Y65‑p, ARPP‑19 (rat): Y65‑p

Y100-p - Calmodulin (human)
Modsite: FDkDGNGyIsAAELr SwissProt Entrez-Gene
Orthologous residues
Calmodulin (human): Y100‑p, Calmodulin (mouse): Y100‑p, Calmodulin (rat): Y100‑p, Calmodulin (chicken): Y100‑p, Calmodulin (sheep): Y100‑p, Calmodulin (cow): Y100‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y552-p - CBL (human)
Modsite: PPPPDRPySVGAESR SwissProt Entrez-Gene
Orthologous residues
CBL (human): Y552‑p, CBL (mouse): Y550‑p, CBL (rat): Y551‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

T14-p - CDK1 (human)
Modsite: IEkIGEGtyGVVykG SwissProt Entrez-Gene
Orthologous residues
CDK1 (human): T14‑p, CDK1 iso2 (human): T14‑p, CDK1 (mouse): T14‑p, CDK1 (rat): T14‑p, CDK1 (chicken): T14‑p, CDK1 (fruit fly): T14‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimuated

Y15-p - CDK1 (human)
Modsite: EkIGEGtyGVVykGR SwissProt Entrez-Gene
Orthologous residues
CDK1 (human): Y15‑p, CDK1 iso2 (human): Y15‑p, CDK1 (mouse): Y15‑p, CDK1 (rat): Y15‑p, CDK1 (chicken): Y15‑p, CDK1 (fruit fly): Y15‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated; di-phosphopeptide, IL-15 treated; mono-phosphopeptide, IL-2 treated; di-phosphopeptide, IL-2 treated; mono-phosphopeptide, unstimuated; di-phosphopeptide, unstimuated; mono-phosphopeptide

T14-p - CDK2 (human)
Modsite: VEkIGEGtyGVVykA SwissProt Entrez-Gene
Orthologous residues
CDK2 (human): T14‑p, CDK2 iso2 (human): T14‑p, CDK2 (mouse): T14‑p, CDK2 (rat): T14‑p

Y15-p - CDK2 (human)
Modsite: EkIGEGtyGVVykAR SwissProt Entrez-Gene
Orthologous residues
CDK2 (human): Y15‑p, CDK2 iso2 (human): Y15‑p, CDK2 (mouse): Y15‑p, CDK2 (rat): Y15‑p

T14-p - CDK3 (human)
Modsite: VEkIGEGtyGVVyKA SwissProt Entrez-Gene
Orthologous residues
CDK3 (human): T14‑p, CDK3 (mouse): T14‑p, CDK3 (cow): T14‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

Y15-p - CDK3 (human)
Modsite: EkIGEGtyGVVyKAK SwissProt Entrez-Gene
Orthologous residues
CDK3 (human): Y15‑p, CDK3 (mouse): Y15‑p, CDK3 (cow): Y15‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

Y15-p - CDK5 (human)
Modsite: EkIGEGtyGtVFkAk SwissProt Entrez-Gene
Orthologous residues
CDK5 (human): Y15‑p, CDK5 (mouse): Y15‑p, CDK5 (rat): Y15‑p, CDK5 (cow): Y15‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

Y171-p - CDKL5 (human)
Modsite: NNANytEyVATRWYR SwissProt Entrez-Gene
Orthologous residues
CDKL5 (human): Y171‑p, CDKL5 iso2 (human): Y171‑p, CDKL5 (mouse): Y171‑p, CDKL5 (rat): Y171‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

Y648-p - DNAH9 (human)
Modsite: GKRMQQKyEDMLSLL SwissProt Entrez-Gene
Orthologous residues
DNAH9 (human): Y648‑p, DNAH9 (mouse): Y646‑p, DNAH9 (rat):
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

S112-p - DNAJC17 (human)
Modsite: RQAQAQEsEEEEESR SwissProt Entrez-Gene
Orthologous residues
DNAJC17 (human): S112‑p, DNAJC17 (mouse): S112‑p, DNAJC17 (rat): T112‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

Y321-p - DYRK1A (human)
Modsite: LGQRIyQyIQsRFYR SwissProt Entrez-Gene
Orthologous residues
DYRK1A (human): Y321‑p, DYRK1A iso2 (human): Y312‑p, DYRK1A iso4 (human): Y321‑p, DYRK1A (mouse): Y321‑p, DYRK1A (rat): Y321‑p, DYRK1A (rabbit):

Y273-p - DYRK1B (human)
Modsite: LGQRIyQyIQsRFYR SwissProt Entrez-Gene
Orthologous residues
DYRK1B (human): Y273‑p, DYRK1B iso2 (human): Y273‑p, DYRK1B (mouse): Y273‑p, DYRK1B (rat): Y273‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

Y44-p - ENO1 (human)
Modsite: sGAstGIyEALELrD SwissProt Entrez-Gene
Orthologous residues
ENO1 (human): Y44‑p, ENO1 (mouse): Y44‑p, ENO1 (rat): Y44‑p, ENO1 (chicken): Y44‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

Y70-p - ENSA (human)
Modsite: kyFDsGDyNMAkAkM SwissProt Entrez-Gene
Orthologous residues
ENSA (human): Y70‑p, ENSA iso2 (human): Y70‑p, ENSA iso3 (human): Y86‑p, ENSA iso5 (human): Y66‑p, ENSA (mouse): Y70‑p, ENSA (rat): Y70‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y690-p - EPRS (human)
Modsite: PyEPVsPysCKEAPC SwissProt Entrez-Gene
Orthologous residues
EPRS (human): Y690‑p, EPRS (mouse): Y690‑p, EPRS (rat): Y664‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimuated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated; di-phosphopeptide, IL-15 treated; mono-phosphopeptide, IL-2 treated; di-phosphopeptide, IL-2 treated; mono-phosphopeptide, unstimuated; di-phosphopeptide, unstimuated; mono-phosphopeptide
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimuated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y221-p - ERK5 (human)
Modsite: HQyFMtEyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
ERK5 (human): Y221‑p, ERK5 iso2 (human): Y82‑p, ERK5 (mouse): Y221‑p, ERK5 (rat): Y221‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y2502-p - FLNB (human)
Modsite: RSSTEtCysAIPKAS SwissProt Entrez-Gene
Orthologous residues
FLNB (human): Y2502‑p, FLNB iso2 (human): Y2478‑p, FLNB iso8 (human): Y2533‑p, FLNB (mouse): Y2502‑p, FLNB (rat): Y2478‑p, FLNB (cow): Y2533‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

Y506-p - GAB3 (human)
Modsite: SREDEESyIEMEEHR SwissProt Entrez-Gene
Orthologous residues
GAB3 (human): Y506‑p, GAB3 iso2 (human): Y507‑p, GAB3 iso3 (human): Y507‑p, GAB3 (mouse): Y515‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y533-p - GAB3 (human)
Modsite: TKKFSLDyLALDFNS SwissProt Entrez-Gene
Orthologous residues
GAB3 (human): Y533‑p, GAB3 iso2 (human): Y534‑p, GAB3 iso3 (human): , GAB3 (mouse): Y542‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y560-p - GAB3 (human)
Modsite: SEEQRVDyVQVDEQK SwissProt Entrez-Gene
Orthologous residues
GAB3 (human): Y560‑p, GAB3 iso2 (human): Y561‑p, GAB3 iso3 (human): Y522‑p, GAB3 (mouse): Y569‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y348-p - GART (human)
Modsite: SKGYPGDytkGVEIT SwissProt Entrez-Gene
Orthologous residues
GART (human): Y348‑p, GART iso2 (human): Y348‑p, GART (mouse): Y348‑p, GART (rat): Y348‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

Y279-p - GSK3A (human)
Modsite: RGEPNVsyICsRyyR SwissProt Entrez-Gene
Orthologous residues
GSK3A (human): Y279‑p, GSK3A (mouse): Y279‑p, GSK3A (rat): Y279‑p, GSK3A (cow): Y279‑p

Y216-p - GSK3B (human)
Modsite: RGEPNVsyICsRyyR SwissProt Entrez-Gene
Orthologous residues
GSK3B (human): Y216‑p, GSK3B iso2 (human): Y216‑p, GSK3B (mouse): Y216‑p, GSK3B (rat): Y216‑p, GSK3B (rabbit): Y216‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

Y352-p - HIPK1 (human)
Modsite: SkAVCstyLQsRYYR SwissProt Entrez-Gene
Orthologous residues
HIPK1 (human): Y352‑p, HIPK1 iso2 (human): Y352‑p, HIPK1 iso4 (human): , HIPK1 (mouse): Y352‑p, HIPK1 (rat): Y352‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

Y361-p - HIPK2 (human)
Modsite: SkAVCstyLQsRYyR SwissProt Entrez-Gene
Orthologous residues
HIPK2 (human): Y361‑p, HIPK2 (mouse): Y361‑p, HIPK2 (rat): Y361‑p

Y336-p - hnRNP A2/B1 (human)
Modsite: GPyGGGNyGPGGsGG SwissProt Entrez-Gene
Orthologous residues
hnRNP A2/B1 (human): Y336‑p, hnRNP A2/B1 iso2 (human): Y324‑p, hnRNP A2/B1 (mouse): Y336‑p, hnRNP A2/B1 iso3 (mouse): Y284‑p, hnRNP A2/B1 (rat): Y336‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

Y222-p - HS1 (human)
Modsite: MEAPttAykkTTPIE SwissProt Entrez-Gene
Orthologous residues
HS1 (human): Y222‑p, HS1 (mouse): Y222‑p, HS1 (rat): Y222‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y627-p - HSP90A (human)
Modsite: RDNstMGyMAAkkHL SwissProt Entrez-Gene
Orthologous residues
HSP90A (human): Y627‑p, HSP90A iso2 (human): Y749‑p, HSP90A (mouse): Y628‑p, HSP90A (rat): Y628‑p, HSP90A (hamster): Y628‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y492-p - HSP90AB3P (human)
Modsite: rDNSTMGyMMAkKHL SwissProt Entrez-Gene
Orthologous residues
HSP90AB3P (human): Y492‑p

Y619-p - HSP90B (human)
Modsite: rDNstMGyMMAkkHL SwissProt Entrez-Gene
Orthologous residues
HSP90B (human): Y619‑p, HSP90B (mouse): Y619‑p, HSP90B (rat): Y619‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y536-p - IL2RB (human)
Modsite: LPLNTDAyLSLQELQ SwissProt Entrez-Gene
Orthologous residues
IL2RB (human): Y536‑p, IL2RB (mouse): Y524‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y553-p - ITSN2 (human)
Modsite: EYQNKLIyLVPEKQL SwissProt Entrez-Gene
Orthologous residues
ITSN2 (human): Y553‑p, ITSN2 iso2 (human): Y553‑p, ITSN2 (mouse): Y554‑p, ITSN2 (rat): Y554‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y785-p - JAK3 (human)
Modsite: NSLIsSDyELLSDPT SwissProt Entrez-Gene
Orthologous residues
JAK3 (human): Y785‑p, JAK3 (mouse): Y781‑p, JAK3 iso2 (mouse): Y1000‑p, JAK3 iso3 (mouse): Y996‑p, JAK3 (rat): Y781‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y185-p - JNK1 (human)
Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p

T183-p - JNK2 (human)
Modsite: ACtNFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK2 (human): T183‑p, JNK2 iso2 (human): T183‑p, JNK2 iso3 (human): T183‑p, JNK2 (mouse): T183‑p, JNK2 (rat): T183‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimuated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y185-p - JNK2 (human)
Modsite: tNFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK2 (human): Y185‑p, JNK2 iso2 (human): Y185‑p, JNK2 iso3 (human): Y185‑p, JNK2 (mouse): Y185‑p, JNK2 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated; di-phosphopeptide, IL-15 treated; mono-phosphopeptide, IL-2 treated; di-phosphopeptide, IL-2 treated; mono-phosphopeptide, unstimuated; di-phosphopeptide, unstimuated; mono-phosphopeptide
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y223-p - JNK3 (human)
Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK3 (human): Y223‑p, JNK3 iso2 (human): Y223‑p, JNK3 (mouse): Y223‑p, JNK3 iso2 (mouse): Y223‑p, JNK3 iso3 (mouse): , JNK3 (rat): Y223‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

Y340-p - KI-67 (human)
Modsite: VGAsFPLyEPAkMkt SwissProt Entrez-Gene
Orthologous residues
KI‑67 (human): Y340‑p, KI‑67 iso2 (human): , KI‑67 (mouse): T309‑p, KI‑67 (rat): T308‑p, KI‑67 iso4 (rat): T308‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

Y2-p - Kv-beta2 (human)
Modsite: ______MyPEsttGs SwissProt Entrez-Gene
Orthologous residues
Kv‑beta2 (human): Y2‑p, Kv‑beta2 iso2 (human): Y2‑p, Kv‑beta2 iso3 (human): , Kv‑beta2 (mouse): Y2‑p, Kv‑beta2 (rat): Y2‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y267-p - MPRIP (human)
Modsite: KVRVEsGyFsLEKTK SwissProt Entrez-Gene
Orthologous residues
MPRIP (human): Y267‑p, MPRIP iso2 (human): Y267‑p, MPRIP iso3 (human): Y267‑p, MPRIP (mouse): Y268‑p, MPRIP iso6 (mouse): Y268‑p, MPRIP (rat): Y273‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y26-p - NUCKS (human)
Modsite: sDDADEDyGrDsGPP SwissProt Entrez-Gene
Orthologous residues
NUCKS (human): Y26‑p, NUCKS (mouse): Y26‑p, NUCKS (rat): Y26‑p, NUCKS (cow): Y26‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

T180-p - P38A (human)
Modsite: RHtDDEMtGyVAtRW SwissProt Entrez-Gene
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p, P38A (salmonid): T181‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimuated

Y182-p - P38A (human)
Modsite: tDDEMtGyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated; di-phosphopeptide, IL-15 treated; mono-phosphopeptide, IL-2 treated; di-phosphopeptide, IL-2 treated; mono-phosphopeptide, unstimuated; di-phosphopeptide, unstimuated; mono-phosphopeptide
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-15 increase

Y185-p - P38G (human)
Modsite: ADsEMtGyVVTRWYR SwissProt Entrez-Gene
Orthologous residues
P38G (human): Y185‑p, P38G (mouse): Y185‑p, P38G (rat): Y185‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-15 increase

Y196-p - PGK1 (human)
Modsite: LMkkELNyFAkALEs SwissProt Entrez-Gene
Orthologous residues
PGK1 (human): Y196‑p, PGK1 (mouse): Y196‑p, PGK1 (rat): Y196‑p, PGK1 (cow): Y196‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

Y317-p - PIK3CA (human)
Modsite: RIstAtPyMNGETST SwissProt Entrez-Gene
Orthologous residues
PIK3CA (human): Y317‑p, PIK3CA (mouse): Y317‑p, PIK3CA (rat): Y317‑p, PIK3CA (cow): Y317‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y105-p - PKM (human)
Modsite: FAsDPILyRPVAVAL SwissProt Entrez-Gene
Orthologous residues
PKM (human): Y105‑p, PKM iso2 (human): Y105‑p, PKM iso3 (human): Y90‑p, PKM (mouse): Y105‑p, PKM (rat): Y105‑p, PKM iso2 (rat): Y105‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

Y783-p - PLCG1 (human)
Modsite: EGRNPGFyVEANPMP SwissProt Entrez-Gene
Orthologous residues
PLCG1 (human): Y783‑p, PLCG1 iso2 (human): Y783‑p, PLCG1 (mouse): Y783‑p, PLCG1 (rat): Y783‑p, PLCG1 (cow): Y783‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimuated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y759-p - PLCG2 (human)
Modsite: LyDVsRMyVDPsEIN SwissProt Entrez-Gene
Orthologous residues
PLCG2 (human): Y759‑p, PLCG2 (mouse): Y759‑p, PLCG2 (rat): Y759‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimuated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y29-p - PPP1R14B (human)
Modsite: GGPGPrVyFQsPPGA SwissProt Entrez-Gene
Orthologous residues
PPP1R14B (human): Y29‑p, PPP1R14B (mouse): Y29‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y230-p - PPP1R18 (human)
Modsite: LsPGEsAyQKLGLTE SwissProt Entrez-Gene
Orthologous residues
PPP1R18 (human): Y230‑p, PPP1R18 iso2 (human): Y230‑p, PPP1R18 (mouse): D230‑p, PPP1R18 (rat): D231‑p, PPP1R18 (cow): N223‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y849-p - PRP4 (human)
Modsite: ADNDItPyLVsRFyR SwissProt Entrez-Gene
Orthologous residues
PRP4 (human): Y849‑p, PRP4 (mouse): Y849‑p, PRP4 (rat): Y849‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

S243-p - PSMA3 (human)
Modsite: AEkYAkEsLkEEDEs SwissProt Entrez-Gene
Orthologous residues
PSMA3 (human): S243‑p, PSMA3 iso2 (human): S236‑p, PSMA3 (mouse): S243‑p, PSMA3 (rat): S243‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

Y161-p - RBM17 (human)
Modsite: DsDEDEDyERERRKR SwissProt Entrez-Gene
Orthologous residues
RBM17 (human): Y161‑p, RBM17 (mouse): Y161‑p, RBM17 (rat): Y161‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

Y34-p - RFFL (human)
Modsite: QAysNPGySsFPsPT SwissProt Entrez-Gene
Orthologous residues
RFFL (human): Y34‑p, RFFL (mouse): Y48‑p, RFFL iso3 (mouse): Y69‑p, RFFL (rat): Y34‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-15 increase

Y278-p - SEPT9 (human)
Modsite: kAPVDFGyVGIDsIL SwissProt Entrez-Gene
Orthologous residues
SEPT9 (human): Y278‑p, SEPT9 iso2 (human): Y260‑p, SEPT9 iso5 (human): Y271‑p, SEPT9 iso7 (human): Y259‑p, SEPT9 iso8 (human): Y166‑p, SEPT9 (mouse): Y276‑p, SEPT9 iso3 (mouse): Y269‑p, SEPT9 (rat): Y258‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y427-p - SHC1 (human)
Modsite: ELFDDPsyVNVQNLD SwissProt Entrez-Gene
Orthologous residues
SHC1 (human): Y427‑p, SHC1 iso2 (human): Y317‑p, SHC1 iso3 (human): Y272‑p, SHC1 iso6 (human): Y428‑p, SHC1 iso7 (human): Y318‑p, SHC1 (mouse): Y423‑p, SHC1 iso2 (mouse): Y313‑p, SHC1 iso3 (mouse): Y268‑p, SHC1 (rat): Y423‑p, SHC1 iso2 (rat): Y313‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y986-p - SHIP-2 (human)
Modsite: NsFNNPAyyVLEGVP SwissProt Entrez-Gene
Orthologous residues
SHIP‑2 (human): Y986‑p, SHIP‑2 iso2 (human): Y744‑p, SHIP‑2 (mouse): Y987‑p, SHIP‑2 (rat): Y987‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y584-p - SHP-2 (human)
Modsite: REDsARVyENVGLMQ SwissProt Entrez-Gene
Orthologous residues
SHP‑2 (human): Y584‑p, SHP‑2 iso2 (human): Y580‑p, SHP‑2 (mouse): Y584‑p, SHP‑2 (rat): Y584‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y441-p - SSRP1 (human)
Modsite: MNPsyDEyADsDEDQ SwissProt Entrez-Gene
Orthologous residues
SSRP1 (human): Y441‑p, SSRP1 (mouse): Y441‑p, SSRP1 (rat): Y441‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

Y374-p - STAM2 (human)
Modsite: EAPVysVysKLHPPA SwissProt Entrez-Gene
Orthologous residues
STAM2 (human): Y374‑p, STAM2 iso2 (human): , STAM2 (mouse): Y374‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y705-p - STAT3 (human)
Modsite: DPGsAAPyLktKFIC SwissProt Entrez-Gene
Orthologous residues
STAT3 (human): Y705‑p, STAT3 iso2 (human): Y704‑p, STAT3 iso3 (human): Y705‑p, STAT3 (mouse): Y705‑p, STAT3 iso2 (mouse): Y705‑p, STAT3 iso3 (mouse): Y704‑p, STAT3 (rat): Y705‑p, STAT3 (cow): Y705‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y693-p - STAT4 (human)
Modsite: TERGDKGyVPSVFIP SwissProt Entrez-Gene
Orthologous residues
STAT4 (human): Y693‑p, STAT4 (mouse): Y694‑p, STAT4 (rat): Y693‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimuated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y694-p - STAT5A (human)
Modsite: LAkAVDGyVkPQIkQ SwissProt Entrez-Gene
Orthologous residues
STAT5A (human): Y694‑p, STAT5A (mouse): Y694‑p, STAT5A iso2 (mouse): , STAT5A (rat): Y694‑p, STAT5A (fruit fly): Y711‑p, STAT5A (sheep): Y694‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimuated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y699-p - STAT5B (human)
Modsite: tAkAVDGyVkPQIkQ SwissProt Entrez-Gene
Orthologous residues
STAT5B (human): Y699‑p, STAT5B (mouse): Y699‑p, STAT5B (rat): Y699‑p

Y192-p - TAGLN2 (human)
Modsite: sQAGMtGyGMPrQIL SwissProt Entrez-Gene
Orthologous residues
TAGLN2 (human): Y192‑p, TAGLN2 (mouse): Y192‑p, TAGLN2 (rat): Y192‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

Y192-p - TAGLN3 (human)
Modsite: sQAGMtGyGMPrQIM SwissProt Entrez-Gene
Orthologous residues
TAGLN3 (human): Y192‑p, TAGLN3 (mouse): Y192‑p, TAGLN3 (rat): Y192‑p

Y732-p - TBCK (human)
Modsite: GGRSSAPyFSAECPD SwissProt Entrez-Gene
Orthologous residues
TBCK (human): Y732‑p, TBCK (mouse): Y732‑p, TBCK iso3 (mouse): Y732‑p, TBCK (rat): Y699‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y20-p - TfR (human)
Modsite: FGGEPLsytRFsLAR SwissProt Entrez-Gene
Orthologous residues
TfR (human): Y20‑p, TfR (mouse): Y20‑p, TfR (rat):
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

Y37-p - UMPS (human)
Modsite: SGLSsPIyIDLRGIV SwissProt Entrez-Gene
Orthologous residues
UMPS (human): Y37‑p, UMPS (mouse): Y37‑p, UMPS (rat): Y37‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

Y844-p - VAV1 (human)
Modsite: VEEDysEyC______ SwissProt Entrez-Gene
Orthologous residues
VAV1 (human): Y844‑p, VAV1 iso2 (human): Y812‑p, VAV1 (mouse): Y844‑p, VAV1 (rat): Y842‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

Y61-p - Vimentin (human)
Modsite: AssPGGVyAtrssAV SwissProt Entrez-Gene
Orthologous residues
Vimentin (human): Y61‑p, Vimentin (mouse): Y61‑p, Vimentin (rat): Y61‑p, Vimentin (rabbit): Y61‑p, Vimentin (hamster): Y60‑p, Vimentin (cow): Y61‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

Y32-p - VPS18 (human)
Modsite: VGIPHsGyVNAQLEk SwissProt Entrez-Gene
Orthologous residues
VPS18 (human): Y32‑p, VPS18 (mouse): Y32‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase

Y291-p - WASP (human)
Modsite: AEtsKLIyDFIEDQG SwissProt Entrez-Gene
Orthologous residues
WASP (human): Y291‑p, WASP (mouse): Y293‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

Y1248-p - XRN1 (human)
Modsite: QGSGkMQyFQPTIQE SwissProt Entrez-Gene
Orthologous residues
XRN1 (human): Y1248‑p, XRN1 iso2 (human): Y1248‑p, XRN1 (mouse): H1245‑p, XRN1 (rat): H1248‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

Y385-p - ZC3H18 (human)
Modsite: RFWrGGQyENFRVQy SwissProt Entrez-Gene
Orthologous residues
ZC3H18 (human): Y385‑p, ZC3H18 iso2 (human): Y409‑p, ZC3H18 (mouse): Y381‑p, ZC3H18 iso2 (mouse): , ZC3H18 (rat): Y380‑p, ZC3H18 iso2 (rat): Y404‑p, ZC3H18 (cow): Y394‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated

Y630-p - ZDHHC5 (human)
Modsite: EPGPtAPyLGRsMsY SwissProt Entrez-Gene
Orthologous residues
ZDHHC5 (human): Y630‑p, ZDHHC5 iso2 (human): Y577‑p, ZDHHC5 (mouse): Y630‑p, ZDHHC5 (rat): Y630‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  leukemia, chronic lymphocytic leukemia
Relevant cell lines - cell types - tissues:  F15R-Kit (T lymphocyte)
Cellular systems studied:  cell lines
Species studied:  human
Comments:  IL-15 treated, IL-2 treated, unstimulated
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
IL-2 increase
IL-15 increase